Log in

Meridian Bioscience Stock Forecast, Price & News

-2.26 (-11.64 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $17.15
50-Day Range
MA: $17.47
52-Week Range
Now: $17.15
Volume880,278 shs
Average Volume741,325 shs
Market Capitalization$735.10 million
P/E Ratio16.65
Dividend YieldN/A
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Read More
Meridian Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:VIVO



Sales & Book Value

Annual Sales$201.01 million
Cash Flow$0.86 per share
Book Value$4.47 per share


Net Income$24.38 million


Market Cap$735.10 million
Next Earnings Date11/13/2020 (Confirmed)
-2.26 (-11.64 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

How has Meridian Bioscience's stock been impacted by COVID-19?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VIVO shares have increased by 166.7% and is now trading at $17.15.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Meridian Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Meridian Bioscience

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Meridian Bioscience

How can I listen to Meridian Bioscience's earnings call?

Meridian Bioscience will be holding an earnings conference call on Friday, November 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its earnings results on Friday, August, 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.31. The firm had revenue of $84.80 million for the quarter, compared to the consensus estimate of $66.12 million. Meridian Bioscience had a net margin of 18.22% and a return on equity of 21.11%.
View Meridian Bioscience's earnings history

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its FY 2020 Pre-Market earnings guidance on Friday, August, 7th. The company provided earnings per share guidance of 1.01-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.75. The company issued revenue guidance of $245-250 million, compared to the consensus revenue estimate of $235.58 million.

What price target have analysts set for VIVO?

3 brokerages have issued 1 year price targets for Meridian Bioscience's stock. Their forecasts range from $8.00 to $34.00. On average, they expect Meridian Bioscience's share price to reach $21.00 in the next year. This suggests a possible upside of 22.4% from the stock's current price.
View analysts' price targets for Meridian Bioscience

Are investors shorting Meridian Bioscience?

Meridian Bioscience saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,920,000 shares, an increase of 24.3% from the September 15th total of 2,350,000 shares. Based on an average trading volume of 672,600 shares, the short-interest ratio is presently 4.3 days. Approximately 6.9% of the shares of the stock are short sold.
View Meridian Bioscience's Short Interest

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, Pres, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 51, Pay $831.14k)
  • Mr. Bryan Baldasare, Exec. VP, Chief Accounting Officer, CFO & Sec.
  • Dr. Lourdes G. Weltzien, Exec. VP of Life Science Bus. Unit
  • Ms. Melissa A. Lueke, Consultant (Age 57, Pay $190.34k)
  • Mr. Jeff Pinkston, Director of Corp. Fin.
  • Mr. Charles Wood, VP of Corp. Strategy, Bus. Devel. & Investor Relations
  • Melissa J. McCarey, VP of Global HR
  • Mr. Tony Serafini-Lamanna, Exec. VP of Diagnostics
  • Ms. Susan D. Rolih, Consultant (Age 71)

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Foundry Partners LLC (0.67%), Cadence Capital Management LLC (0.08%), Exchange Traded Concepts LLC (0.06%), Louisiana State Employees Retirement System (0.05%), LSV Asset Management (0.04%) and Bowling Portfolio Management LLC (0.04%). Company insiders that own Meridian Bioscience stock include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini.
View institutional ownership trends for Meridian Bioscience

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Meridian Bioscience

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was purchased by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Cadence Capital Management LLC, LSV Asset Management, Bowling Portfolio Management LLC, Campbell & CO Investment Adviser LLC, Louisiana State Employees Retirement System, BNP Paribas Arbitrage SA, and USA Financial Portformulas Corp. Company insiders that have bought Meridian Bioscience stock in the last two years include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $17.15.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $735.10 million and generates $201.01 million in revenue each year. The company earns $24.38 million in net income (profit) each year or $0.68 on an earnings per share basis. Meridian Bioscience employs 660 workers across the globe.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.